Nonetheless, low - dose computed tomography screens may change diagnostic prospects in the future, and recently developed therapies targeting tumors harboring mutations in EGFR or
ALK receptors are showing promise.
Not exact matches
Multiplexed genetic screening for epidermal growth factor
receptor (EGFR) and anaplastic lymphoma kinase (
ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
The advent of therapies directed at tumors with mutations in epidermal growth factor
receptor (EGFR), anaplastic lymphoma kinase (
ALK), and B - Raf proto - oncogene (BRAF) genes over the past decade have dramatically changed outcomes, he says.
This disorder is associated with mutations in members of the TGF ‐ β
receptor superfamily, including bone morphogenetic protein
receptor ‐ 2 (BMPR ‐ 2),
Alk ‐ 1, and endoglin.